Uploaded April 2018 | Updated September 2026, 1 week ago
Professor Mark Emberton is a surgeon and Dean of Faculty of Medical science at UCL. He explains his #research into more accurate #diagnosis for #prostatecancer as part of the reIMAGINE Project.
The ReIMAGINE consortium seeks to change forever the way in which prostate cancer is diagnosed, the manner in which it is classified, the method by which risk is communicated, the utility associated with the diagnosis, the benefit that is derived from intervention and reduce the overall costs of care.
The precise risk-stratification that results from an image-based measurable-disease approach will allow determination of whether progression in prostate cancer is clonally specified or is a transitional phenomenon.
The risk stratification of prostate cancer that will emerge from ReIMAGINE will permit a departure from today’s one-size-fits-all approach towards an individualised care that matches the very broad risk profile of this ill understood disease.
Learn more ▶️ukri.org/about-us/mrc
Let’s connect!
Twitter 🔗 twitter.com/The_MRC
LinkedIn 🔗 linkedin.com/company/medical-research-council
YouTube 🔗 youtube.com/c/medicalresearchcouncil
Instagram 🔗 instagram.com/weareukri
We think you’ll like…
Health Data Research UK | Interview with Professor Andrew Morris, Director
▶️ youtube.com/watch?v=BojvZOzYeq4
Regenerative Medicine | Interview with Professor Robin Ali
▶️ youtube.com/watch?v=zTgR9BnNZ-0
ABOUT THE MEDICAL RESEARCH COUNCIL (MRC)
The Medical Research Council (MRC) improves the health of people in the UK – and around the world – by supporting excellent science, and training the very best scientists.
Find out more ▶️ ukri.org/councils/MRC
#MRC #Medicine #MedicalSciences #MedicalResearch #Innovation #Health
Professor Mark Emberton is a surgeon and Dean of Faculty of Medical science at UCL. He explains his #research into more accurate #diagnosis for #prostatecancer as part of the reIMAGINE Project.
The ReIMAGINE consortium seeks to change forever the way in which prostate cancer is diagnosed, the manner in which it is classified, the method by which risk is communicated, the utility associated with the diagnosis, the benefit that is derived from intervention and reduce the overall costs of care.
The precise risk-stratification that results from an image-based measurable-disease approach will allow determination of whether progression in prostate cancer is clonally specified or is a transitional phenomenon.
The risk stratification of prostate cancer that will emerge from ReIMAGINE will permit a departure from today’s one-size-fits-all approach towards an individualised care that matches the very broad risk profile of this ill understood disease.
Learn more ▶️ukri.org/about-us/mrc
Let’s connect!
Twitter 🔗 twitter.com/The_MRC
LinkedIn 🔗 linkedin.com/company/medical-research-council
YouTube 🔗 youtube.com/c/medicalresearchcouncil
Instagram 🔗 instagram.com/weareukri
We think you’ll like…
Health Data Research UK | Interview with Professor Andrew Morris, Director
▶️ youtube.com/watch?v=BojvZOzYeq4
Regenerative Medicine | Interview with Professor Robin Ali
▶️ youtube.com/watch?v=zTgR9BnNZ-0
ABOUT THE MEDICAL RESEARCH COUNCIL (MRC)
The Medical Research Council (MRC) improves the health of people in the UK – and around the world – by supporting excellent science, and training the very best scientists.
Find out more ▶️ ukri.org/councils/MRC
#MRC #Medicine #MedicalSciences #MedicalResearch #Innovation #Health
